NTRK is emerging as an actionable biomarker and oncogenic driver across a wide range of tumour types1–9
NTRK fusions have been identified in at least
25 tumour types in adult and paediatric patients, including:1–9
NTRK fusion+ cancer currently has no known defining clinical or pathological features. Only high-quality molecular testing such as next-generation sequencing (NGS) can confirm its presence1
ESMO proposal: NTRK testing10
It is important to ensure that the diagnostic test covers NTRK 1, 2, 3 fusion genes and is validated with appropriate reference standards.
Figure adapted from Marchio C. et al , 2019.
High-quality molecular testing is needed to uncover NTRK fusion+ cancer1,11,12
TRK fusion proteins drive cancer through aberrant signalling1,3-6
ESMO, European Society for Medical Oncology; FISH, DNA fluorescence in situ hybridisation; IHC, immunohistochemistry; NGS, next-generation sequencing; RT-PCR, reverse-transcriptase polymerase chain reaction.
1. Vaishnavi A, Le AT, Doebele RC. Cancer Discov 2015;5:25–34.
2. Lange AM, Lo HW. Cancers (Basel) 2018;10.
3. Amatu A, Sartore-Bianchi A, Siena S. ESMO Open 2016;1:e000023.
4. Khotskaya YB, et al. Pharmacol Ther 2017;173:58–66.
5. de Lartigue J. TRK inhibitors advance rapidly in “tumor-agnostic” paradigm. OncologyLive 2017;18. Available at: https://www.onclive.com/publications/oncology-live/2017/vol-18-no-15/trk-inhibitors-advance-rapidly-in-tumoragnostic-paradigm (Accessed July 2020).
6. Robbins HL, Hague A. Front Endocrinol (Lausanne) 2016;6:1–22.
7. Dupain C, et al. Mol Ther Nucleic Acids 2017;6:315–326.
8. Kummar S, Lassen UN. Target Oncol 2018;13:545–556.
9. Cocco E, Scaltriti M, Drilon A. Nat Rev Clin Oncol 2018;15:731–747.
10. Marchio C. et al. Ann Oncol 2019;30:1417–1427.
11. Murphy DA, et al. Appl Immunohisochem Mol Morphol 2017;25:513–523.
12. Rogers TM, et al. Sci Rep 2017;7:1–8.
13. Chong CR, et al. Clin Cancer Res 2017;23:204–213.
14. Stransky N, et al. Nat Commun 2014;5:4846.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
This global website is intended for healthcare professionals outside the UK, US and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.